We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 12.00 | 29,543 | 07:30:57 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10.00 | 14.00 | 12.00 | 12.00 | 12.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 149k | -7.14M | -0.1078 | -1.11 | 7.95M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:02:08 | O | 129 | 13.90 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/6/2025 | 15:01 | ALNC |  Celadon evades administration with new loan amid plans to delist |
| 11/6/2025 | 07:00 | UK RNS | Celadon Pharmaceuticals PLC New Committed Credit Facility |
| 06/6/2025 | 15:55 | UK RNS | Celadon Pharmaceuticals PLC Funding Update, Notice of AGM |
| 30/5/2025 | 18:07 | UK RNS | Celadon Pharmaceuticals PLC Funding Update |
| 30/4/2025 | 07:00 | UK RNS | Celadon Pharmaceuticals PLC Funding Update |
| 08/4/2025 | 15:05 | UK RNS | Celadon Pharmaceuticals PLC Termination of Facility |
| 31/3/2025 | 15:15 | UK RNS | Celadon Pharmaceuticals PLC Funding Update |
| 24/3/2025 | 10:45 | ALNC | EXECUTIVE CHANGES: Johnson Service Group hires new CFO from Treatt |
| 24/3/2025 | 07:00 | UK RNS | Celadon Pharmaceuticals PLC Board Changes and De-Listing Proposal |
| 19/3/2025 | 07:00 | UK RNS | Celadon Pharmaceuticals PLC Funding Update |
Celadon Pharmaceuticals (CEL) Share Charts1 Year Celadon Pharmaceuticals Chart |
|
1 Month Celadon Pharmaceuticals Chart |
Intraday Celadon Pharmaceuticals Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 06/6/2025 | 19:58 | Celadon Pharmaceuticals Plc | 162 |
| 19/3/2023 | 16:34 | Caparo Energy | 23 |
| 10/10/2009 | 18:30 | Celsis - Sales and Profits grow | 1,036 |
| 06/6/2008 | 16:22 | Chris Evans - Biotech Guru | 1,401 |
| 04/7/2007 | 09:03 | Celsis - Bios that make money | 23 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 09:02:09 | 13.90 | 129 | 17.93 | O |
| 09:01:54 | 13.90 | 57 | 7.92 | O |
| 09:01:31 | 10.35 | 4,946 | 511.96 | O |
| 08:59:33 | 14.00 | 28 | 3.92 | O |
| 07:52:19 | 13.00 | 19,230 | 2,499.90 | O |
| Top Posts |
|---|
Posted at 23/6/2025 09:20 by Celadon Pharmaceuticals Daily Update Celadon Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker CEL. The last closing price for Celadon Pharmaceuticals was 12p.Celadon Pharmaceuticals currently has 66,220,807 shares in issue. The market capitalisation of Celadon Pharmaceuticals is £7,946,497. Celadon Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.11. This morning CEL shares opened at 12p |
Posted at 30/4/2025 07:50 by tomboyb On the verge of going out as well -30/04/2025 7:00am RNS Regulatory News RNS Number : 6909G Celadon Pharmaceuticals PLC 30 April 2025 Celadon Pharmaceuticals Plc ("Celadon", the "Group" or the "Company") Funding Update London, 30 April 2025 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, provides an update on its financial position. Further to the announcement made by the Company on 31 March 2025 the Company has still yet to receive requested funds under its secured credit facility. The Company continues to be engaged with the provider of the facility in relation to securing funds, however there has not been material developments from previous announcements. The Company continues to seek and engage with alternative providers of finance, however there can be no certainty in securing additional funding or, if successful, the timing of such funding. On 31 March 2025, Celadon announced it had limited working capital but continued to benefit from the support of creditors. This support continues and the Company believes it can now trade into May 2025. As set out previously in the event that the Company cannot secure funds in a timely manner, the directors will have to protect the interests of all stakeholders which may lead to the company being placed into administration with limited notice. A further announcement will be made as and when appropriate. |
Posted at 02/4/2025 16:25 by jaknife Zen12,"Shorters getting wacked wacked wacked lol" Have you looked at the chart? Anyone who has shorted Celadon in the last year is quids in, other than anyone who happened to short it yesterday. But anyone shorting a £2m market cap company (which is what CEL was yesterday) is nuts! I would bet that no one shorted CEL yesterday. All the recent selling will be longers rushing for the exit in advance of the probable administration. JakNife |
Posted at 24/3/2025 09:42 by jaknife I'm amazed that the share price is at 11.5p. That's a £7.6m market cap for a company that will be insolvent in less than a year!The last balance sheet showed net assets of £2.45m and, since then, they've spent masses and struggled to raise cash. It should be closer to 1p! JakNife |
Posted at 26/2/2025 16:12 by jaknife Let me make a quick note and we can come back and discuss this again when the results come out:================ 26 Feb 2025, Karimgrant posts suggesting that Celadon is a buy when the share price is 24p. ================ The finals came out on 14 May last year, let's see what the share price is when they come out this year. JakNife |
Posted at 17/1/2025 15:15 by sea7 1. The harvests grown under licence by Valeos will enable Celadon to supply product to its current European customer ahead of completing the fit out of Celadon's Phase 2, which could be worth up to c.£8m per annum, and generate a margin on the difference between the price received from its European customer and the price paid to Valeos.2. In return for the 5 year licence and the use of its genetics Celadon will receive 50 per cent. of the increased contribution from the refitted facility, based on increased yield and/or increased pricing above an agreed minimum level. Subject to the level of sales and increase in yield generated by Valeos this could be worth up to £1.7 million per annum to Celadon, who has the annual right to choose whether this is settled in cash or equity in Valeos ... whilst the deal may bring in £8.7m a year -not all of that goes to celadon- half of the deal looks to be only 50% to celadon. The expected uplifts and revenues are based on prices staying at £10 a gram. In fairness they could rise, however, they could also drop |
Posted at 17/1/2025 14:57 by sea7 jaknife - As advised on 20 December 2024, receipt of these funds, along with expected cash receipts from customers and continuing to work with creditors gives the Company sufficient working capital up to March 2025.key words "up to march 2025" - this could mean 1st March and not end march. Meaning possibly only 6 weeks money left. this bit of news whilst being good, doesn't say how much the first invoice is for. this does appear to have all the hallmarks of a pump, followed by bookbuild fundraise soon. I would not be surprised to see an after hours rns talking of completed bookbuild today -seen that so many times before! I have watched this since it listed and always felt it was only worth about 4p a share, hence not bought any shares in it as yet. Looks like my 4p could be a tad overvalued, unless they start showing the cash coming in and by that I mean actual revenue, not expected or anticipated |
Posted at 17/1/2025 14:44 by jaknife Why so generous?With 68.85m shares in issue ( 15p would value the company at £10.3m. And yet: Balance Sheet The last reported balance sheet was the June interims, which showed net equity of just £2.5m and negligible cash: Post that date they claimed to raise £1.05m at 40p a share in September. Can we be sure that those funds have arrived? There is obviously something skanky about the way that CEL goes about raising funds (relative to the rest of the companies on AIM) as they make gloriously grand announcements about the fund raises but then have to admit, many many months AFTER the date of the announcement, that the funds haven't actually arrived in full! Regardless, let's assume that the full £1.05m did arrive. But they have burnt about £2.5m of cash every six months so where does that put them now? That would imply that net assets decreased by £1.5m as at the end of Dec. Is the balance sheet just a net £1m at year-end? Sales CEL have put out various wild claims of big sales contracts, eg: Inaugural Supply Contract Win which included: "Under the terms of the contract, Celadon will sell a minimum of £3 million worth of product over the next three years, with the first shipment expected in Q4 2023. At the end of the three years, the contract can be extended for a further two years with the mutual agreement of the parties." And yet I refer you again to the interims that show revenues of just £63k for the first six months of 2024! Surely £3m over 3 years means £500k every six months? Did they lie in the original RNS? Or is there a problem? In which case why haven't they updated the market and explained? conclusion Frankly Celadon looks an awful business. The directors have published numerous RNSs that we can now objectively demonstrate with hindsight were either completely untrue or contained wildly optimistic unstated assumptions. How can we trust *ANY* RNS that they publish? They are burning £2.5m every six months and reported on 2 January that they only had enough cash to keep them going to the end of March. Obviously they need to raise funds. If they want to keep going for at least a year then they should raise a minimum of £5m (or else massively cut their cost base). But frankly I value this company at no more than its net assets, which I estimate is about £1m and hence if they raise at more than 1.5p then that would be excessively generous! JakNife |
Posted at 06/12/2024 08:45 by zen12 Could be the biggest recovery stock of the year, BoD sound upbeat and think about it why would they subscribe at £1.05/share if they were going under!! |
Posted at 06/12/2024 08:31 by meek Exactly what I was thinking. Clearly they know the long term future is bright. Once they get past this period of teething problems around funding, I expect the share price to recover quickly. Great time to buy imo. |
Posted at 06/12/2024 08:20 by zen12 £1.05/share investor knows what this is worth...happy to subscribe at this price when share price is 16p...tells you all that you need to know. Very positive news. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
